278 related articles for article (PubMed ID: 8794983)
1. Permeation characteristics of 8-methoxypsoralen through human skin; relevance to clinical treatment.
Anigbogu AN; Williams AC; Barry BW
J Pharm Pharmacol; 1996 Apr; 48(4):357-66. PubMed ID: 8794983
[TBL] [Abstract][Full Text] [Related]
2. Penetration kinetics of 8-methoxypsoralen after 8-methoxypsoralen bath procedure with and without UVA irradiation.
Neumann NJ; Grosse OJ; Ruzicka T; Lehmann P
Skin Pharmacol Appl Skin Physiol; 2001; 14(4):210-6. PubMed ID: 11464103
[TBL] [Abstract][Full Text] [Related]
3. Spatial distribution of 8-methoxypsoralen penetration into human skin after systemic or topical administration.
Grundmann-Kollmann M; Podda M; Bräutigam L; Hardt-Weinelt K; Ludwig RJ; Geisslinger G; Kaufmann R; Tegeder I
Br J Clin Pharmacol; 2002 Nov; 54(5):535-9. PubMed ID: 12445034
[TBL] [Abstract][Full Text] [Related]
4. Psoralens percutaneous permeation across the human whole skin and the epidermis in respect to their polarity (in vitro study).
Saïd A; Makki S; Muret P; Humbert P; Millet J
J Dermatol Sci; 1997 Feb; 14(2):136-44. PubMed ID: 9039977
[TBL] [Abstract][Full Text] [Related]
5. Nanoemulsion containing 8-methoxypsoralen for topical treatment of dermatoses: Development, characterization and ex vivo permeation in porcine skin.
Oliveira CA; Gouvêa MM; Antunes GR; Freitas ZMF; Marques FFC; Ricci-Junior E
Int J Pharm; 2018 Aug; 547(1-2):1-9. PubMed ID: 29800737
[TBL] [Abstract][Full Text] [Related]
6. Effect of polyamidoamine dendrimer G3 and G4 on skin permeation of 8-methoxypsoralene--in vivo study.
Borowska K; Wołowiec S; Rubaj A; Głowniak K; Sieniawska E; Radej S
Int J Pharm; 2012 Apr; 426(1-2):280-283. PubMed ID: 22310461
[TBL] [Abstract][Full Text] [Related]
7. Kinetics and dose-response of photosensitivity in cream psoralen plus ultraviolet A photochemotherapy: comparative in vivo studies after topical application of three standard preparations.
Grundmann-Kollmann M; Tegeder I; Ochsendorf FR; Zollner TM; Ludwig R; Kaufmann R; Podda M
Br J Dermatol; 2001 May; 144(5):991-5. PubMed ID: 11359386
[TBL] [Abstract][Full Text] [Related]
8. Phototesting in bath-PUVA: marked reduction of 8-methoxypsoralen (8-MOP) activity within one hour after an 8-MOP bath.
Schempp CM; Schöpf E; Simon JC
Photodermatol Photoimmunol Photomed; 1996 Jun; 12(3):100-2. PubMed ID: 8956358
[TBL] [Abstract][Full Text] [Related]
9. Cancer incidence among Finnish psoriasis patients treated with 8-methoxypsoralen bath PUVA.
Hannuksela-Svahn A; Pukkala E; Koulu L; Jansén CT; Karvonen J
J Am Acad Dermatol; 1999 May; 40(5 Pt 1):694-6. PubMed ID: 10321595
[TBL] [Abstract][Full Text] [Related]
10. Bath-5-methoxypsoralen-UVA therapy for psoriasis.
Calzavara-Pinton PG; Zane C; Carlino A; De Panfilis G
J Am Acad Dermatol; 1997 Jun; 36(6 Pt 1):945-9. PubMed ID: 9204060
[TBL] [Abstract][Full Text] [Related]
11. Skin permeation of 5-methoxypsoralen from topical dosage forms.
Colombo G; Artusi M; Santi P; Colombo P; Bettini R; Zucchi A; Nicoli S
Drug Dev Ind Pharm; 2003 Feb; 29(2):247-51. PubMed ID: 12648022
[TBL] [Abstract][Full Text] [Related]
12. [Penetration kinetics of xanthotoxin across human skin and stratum corneum].
Wang LY; Jöelle M; Huang FF; Yang DP
Yao Xue Xue Bao; 2006 Sep; 41(9):878-81. PubMed ID: 17111837
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 8-MOP aqueous bath and 8-MOP ethanolic lotion (Meladinine) in local PUVA therapy.
Shephard SE; Schregenberger N; Dummer R; Panizzon RG
Dermatology; 1998; 197(1):25-30. PubMed ID: 9693181
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo study of 5-methoxypsoralen skin concentration after topical application.
Colombo G; Zucchi A; Allegra F; Colombo P; Zani F; Santi P
Skin Pharmacol Appl Skin Physiol; 2003; 16(2):130-6. PubMed ID: 12637789
[TBL] [Abstract][Full Text] [Related]
15. Correlation between 8-methoxypsoralen bath-water concentration and photosensitivity in bath-PUVA treatment.
Tanew A; Kipfelsperger T; Seeber A; Radakovic-Fijan S; Hönigsmann H
J Am Acad Dermatol; 2001 Apr; 44(4):638-42. PubMed ID: 11260539
[TBL] [Abstract][Full Text] [Related]
16. High plasma levels of 8-methoxypsoralen following bath water delivery in dermatological patients.
Kappes UP; Barta U; Merkel U; Balogh A; Elsner P
Skin Pharmacol Appl Skin Physiol; 2003; 16(5):305-12. PubMed ID: 12907835
[TBL] [Abstract][Full Text] [Related]
17. Time course of 8-methoxypsoralen-induced skin photosensitization in PUVA-bath photochemotherapy.
Reuther T; Gruss C; Behrens S; von Kobyletzki G; Neumann N; Lehmann P; Altmeyer P; Kerscher M
Photodermatol Photoimmunol Photomed; 1997; 13(5-6):193-6. PubMed ID: 9542757
[TBL] [Abstract][Full Text] [Related]
18. Transdermal delivery of buprenorphine through cadaver skin.
Roy SD; Roos E; Sharma K
J Pharm Sci; 1994 Feb; 83(2):126-30. PubMed ID: 8169777
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic behaviour of sublingually administered 8-methoxypsoralen for PUVA therapy.
Shephard SE; Langguth P; Panizzon RG
Photodermatol Photoimmunol Photomed; 2001 Feb; 17(1):11-21. PubMed ID: 11169171
[TBL] [Abstract][Full Text] [Related]
20. Topical 8-methoxypsoralen enhances the therapeutic results of targeted narrowband ultraviolet B phototherapy for plaque-type psoriasis.
Asawanonda P; Amornpinyokeit N; Nimnuan C
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):50-5. PubMed ID: 18181973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
